PMID- 37236040
OWN - NLM
STAT- MEDLINE
DCOM- 20230609
LR  - 20230619
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Linking)
VI  - 82
DP  - 2023 Jun
TI  - Harnessing dendritic cell diversity in cancer immunotherapy.
PG  - 102341
LID - S0952-7915(23)00060-2 [pii]
LID - 10.1016/j.coi.2023.102341 [doi]
AB  - Dendritic cells (DCs) are ubiquitous immune cells endowed with a unique capacity 
      to initiate antigen-specific immunity and tolerance. Owing to their unique 
      functional attributes, DCs have long been considered ideal candidates for the 
      induction of effective antitumour responses. At the forefront of the 
      cancer-immunity cycle, attempts to harness DC natural adjuvant properties in the 
      clinic have resulted so far in suboptimal antitumour responses. A better 
      understanding of the heterogeneity of the DC network and its dynamics within the 
      tumour microenvironment will provide a blueprint to fully capitalise on their 
      functional properties to achieve more effective antitumour responses. In this 
      review, we will briefly summarise the origin and heterogeneity of the DC network, 
      their roles in shaping antitumour immunity and in modulating the response to 
      immune checkpoint blockade therapies.
CI  - Crown Copyright (c) 2023. Published by Elsevier Ltd. All rights reserved.
FAU - Park, Hae-Young
AU  - Park HY
AD  - Department of Biochemistry, Monash Biomedicine Discovery Institute, Monash 
      University, 15 Innovation Walk, Clayton, VIC 3800, Australia.
FAU - Ashayeripanah, Mitra
AU  - Ashayeripanah M
AD  - Department of Biochemistry, Monash Biomedicine Discovery Institute, Monash 
      University, 15 Innovation Walk, Clayton, VIC 3800, Australia.
FAU - Chopin, Michael
AU  - Chopin M
AD  - Department of Biochemistry, Monash Biomedicine Discovery Institute, Monash 
      University, 15 Innovation Walk, Clayton, VIC 3800, Australia. Electronic address: 
      Michael.chopin@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230524
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
SB  - IM
MH  - Humans
MH  - *Neoplasms
MH  - Immunotherapy
MH  - Dendritic Cells
MH  - Tumor Microenvironment
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/27 09:42
MHDA- 2023/06/09 06:42
CRDT- 2023/05/26 18:06
PHST- 2022/11/18 00:00 [received]
PHST- 2023/04/23 00:00 [revised]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/05/27 09:42 [pubmed]
PHST- 2023/05/26 18:06 [entrez]
AID - S0952-7915(23)00060-2 [pii]
AID - 10.1016/j.coi.2023.102341 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2023 Jun;82:102341. doi: 10.1016/j.coi.2023.102341. Epub 2023 
      May 24.